	US 7,579,186 B1
	Human monoclonal antibody against TGF-β type II receptor and medicinal use thereof
Shinji Sakamoto, Kanagawa (Japan); and Masafumi Kamada, Kanagawa (Japan)
Assigned to Amgen Fremont Inc., South San Francisco, Calif. (US)
Appl. No. 10/130,034 PCT Filed Nov. 17, 2000, PCT No. PCT/JP00/08129 § 371(c)(1), (2), (4) Date Aug. 23, 2002, PCT Pub. No. WO01/36642, PCT Pub. Date May 25, 2001.
Claims priority of application No. 11-328681 (JP), filed on Nov. 18, 1999; and application No. 2000-340216 (JP), filed on Nov. 08, 2000.
Int. Cl. C12N 5/06 (2006.01); C07K 16/28 (2006.01)

U.S. Cl. 435—325 [530/388.1; 530/388.15; 530/388.22]

29 Claims

1. A human monoclonal antibody or monoclonal antibody fragment that binds to a human TGF-β type II receptor, wherein a heavy chain variable region of the human monoclonal antibody or monoclonal antibody fragment is encoded by a V region DNA derived from a V gene segment selected from 3-07 (DP-54), 5-51 (DP-73) and 3-21 (DP-77) and wherein the human monoclonal antibody or monoclonal antibody fragment has one or more activities selected from:

(a) suppression of human TGF-β1 stimulus-induced cell growth of human osteosarcoma cell line MG-63;

(b) suppression of human TGF-β1 stimulus-induced suppression of cell growth of human lung cancer cell line A549; and

(c) suppression of human TGF-β1 stimulus-induced production of a fibronectin or connective tissue growth factor by human osteosarcoma cell line MG-63.